Use of a fluoropolymer-based paclitaxel-eluting stent for arteriovenous graft outflow vein stenosis in hemodialysis patients

Abstract

We implanted a fluoropolymer-based paclitaxel-eluting stent (FP-PES) in four hemodialysis patients with refractory outflow venous stenosis of their arteriovenous graft. The mean observation period after FP-PES implantation was 11.5 6 4.7 months (range, 7.0-18.0 months). After FP-PES implantation, the patients were evaluated by ultrasound every 3 months. No of the patients experienced neointimal hyperplasia in the stents during the observation period, and no reintervention was performed. FP-PESs could be an attractive alternative to percutaneous transluminal angioplasty for patients with refractory outflow venous stenosis of arteriovenous hemodialysis grafts.

Pathological evaluation of a fluoropolymer-based drug-eluting stent in an arteriovenous graft outflow venous stenosis

“…Recently, fluoropolymer-based drug-eluting stents (FP-DESs) have emerged as a promising option for addressing dysfunctional AVGs, with encouraging reports of their efficacy. 4 , 5 However, a crucial gap exists in our understanding of the long-term vascular response to FP-DES implantation in the outflow veins of AVGs, because no prior studies have investigated this aspect through pathological evaluation. This present work aims to bridge this gap by presenting a unique case with a pathological assessment of an FP-DES retrieved 2.5 years after its placement in an AVG outflow vein.…”